276 related articles for article (PubMed ID: 37286557)
21. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
Krop IE; Masuda N; Mukohara T; Takahashi S; Nakayama T; Inoue K; Iwata H; Yamamoto Y; Alvarez RH; Toyama T; Takahashi M; Osaki A; Saji S; Sagara Y; O'Shaughnessy J; Ohwada S; Koyama K; Inoue T; Li L; Patel P; Mostillo J; Tanaka Y; Sternberg DW; Sellami D; Yonemori K
J Clin Oncol; 2023 Dec; 41(36):5550-5560. PubMed ID: 37801674
[TBL] [Abstract][Full Text] [Related]
22. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
[TBL] [Abstract][Full Text] [Related]
24. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Strickler JH; Cercek A; Siena S; André T; Ng K; Van Cutsem E; Wu C; Paulson AS; Hubbard JM; Coveler AL; Fountzilas C; Kardosh A; Kasi PM; Lenz HJ; Ciombor KK; Elez E; Bajor DL; Cremolini C; Sanchez F; Stecher M; Feng W; Bekaii-Saab TS;
Lancet Oncol; 2023 May; 24(5):496-508. PubMed ID: 37142372
[TBL] [Abstract][Full Text] [Related]
25. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Yamaguchi K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Lee J; Shimoyama T; Lee KW; Saito K; Kawaguchi Y; Kamio T; Kojima A; Sugihara M; Shitara K
J Clin Oncol; 2023 Feb; 41(4):816-825. PubMed ID: 36379002
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T
Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804
[TBL] [Abstract][Full Text] [Related]
28. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A; Rijavec E; Grossi F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
[TBL] [Abstract][Full Text] [Related]
29. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
Rugo HS; Crossno CL; Gesthalter YB; Kelley K; Moore HB; Rimawi MF; Westbrook KE; Buys SS
JCO Oncol Pract; 2023 Aug; 19(8):539-546. PubMed ID: 37207306
[TBL] [Abstract][Full Text] [Related]
30. Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer.
Shimomura A; Takano T; Takahashi S; Sagara Y; Watanabe J; Tokunaga E; Shinkai T; Kamio T; Kikumori K; Kamiyama E; Fujisaki Y; Saotome D; Yamashita T
Clin Pharmacol Ther; 2023 Jan; 113(1):160-169. PubMed ID: 36164935
[TBL] [Abstract][Full Text] [Related]
31. Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study.
Shitara K; Yamaguchi K; Muro K; Yasui H; Sakai D; Oshima T; Fujimura M; Sato Y; Yamazaki S; Wakabayashi T; Sugihara M; Kamio T; Shoji H
Int J Clin Oncol; 2024 Jan; 29(1):27-35. PubMed ID: 37964066
[TBL] [Abstract][Full Text] [Related]
32. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.
Kumagai K; Aida T; Tsuchiya Y; Kishino Y; Kai K; Mori K
Cancer Sci; 2020 Dec; 111(12):4636-4645. PubMed ID: 33051938
[TBL] [Abstract][Full Text] [Related]
33. Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
Nakajima H; Harano K; Nakai T; Kusuhara S; Nakao T; Funasaka C; Kondoh C; Matsubara N; Naito Y; Hosono A; Mitsunaga S; Ishii G; Mukohara T
Breast; 2022 Feb; 61():136-144. PubMed ID: 34999427
[TBL] [Abstract][Full Text] [Related]
34. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.
Mosele F; Deluche E; Lusque A; Le Bescond L; Filleron T; Pradat Y; Ducoulombier A; Pistilli B; Bachelot T; Viret F; Levy C; Signolle N; Alfaro A; Tran DTN; Garberis IJ; Talbot H; Christodoulidis S; Vakalopoulou M; Droin N; Stourm A; Kobayashi M; Kakegawa T; Lacroix L; Saulnier P; Job B; Deloger M; Jimenez M; Mahier C; Baris V; Laplante P; Kannouche P; Marty V; Lacroix-Triki M; Diéras V; André F
Nat Med; 2023 Aug; 29(8):2110-2120. PubMed ID: 37488289
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab Deruxtecan in
Li BT; Smit EF; Goto Y; Nakagawa K; Udagawa H; Mazières J; Nagasaka M; Bazhenova L; Saltos AN; Felip E; Pacheco JM; Pérol M; Paz-Ares L; Saxena K; Shiga R; Cheng Y; Acharyya S; Vitazka P; Shahidi J; Planchard D; Jänne PA;
N Engl J Med; 2022 Jan; 386(3):241-251. PubMed ID: 34534430
[TBL] [Abstract][Full Text] [Related]
37. Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.
Kabraji S; Ni J; Sammons S; Li T; Van Swearingen AED; Wang Y; Pereslete A; Hsu L; DiPiro PJ; Lascola C; Moore H; Hughes M; Raghavendra AS; Gule-Monroe M; Murthy RK; Winer EP; Anders CK; Zhao JJ; Lin NU
Clin Cancer Res; 2023 Jan; 29(1):174-182. PubMed ID: 36074155
[TBL] [Abstract][Full Text] [Related]
38. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
Mishima S; Shitara K
Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395
[No Abstract] [Full Text] [Related]
39. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
Bartsch R
Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
[TBL] [Abstract][Full Text] [Related]
40. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.
Narayan P; Dilawari A; Osgood C; Feng Z; Bloomquist E; Pierce WF; Jafri S; Kalavar S; Kondratovich M; Jha P; Ghosh S; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
J Clin Oncol; 2023 Apr; 41(11):2108-2116. PubMed ID: 36780610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
